Vor Biopharma Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vor Biopharma Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($695.98M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($116.91M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($117.86M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($92.09M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($68.90M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($43.34M) | Mar 14, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($371.64M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($121.19M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($126.04M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($93.42M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($69.02M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($43.37M) | Mar 14, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $321.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $93.31M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $94.32M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $64.55M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $47.53M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $31.62M | Mar 14, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($142.71M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($99.66M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($100.29M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($85.14M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($69.14M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($36.29M) | Mar 14, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $941.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $229.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.07M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.46M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $3.89M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.16M | Mar 14, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $464.13M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $142.89M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $198.13M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $299.37M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $242.59M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $75.91M | Mar 14, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $628.44M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $46.23M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $47.40M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $48.76M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $26.33M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $27.64M | Mar 14, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($164.31M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $96.66M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $150.72M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $250.61M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $216.26M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | ($59.07M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($17.43M) | Mar 14, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.15B) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($456.99M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($340.08M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($222.22M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($130.12M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($61.22M) | Mar 14, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $396.49M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $81.95M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $31.36M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $57.71M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $119.80M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $48.54M | Mar 14, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (70) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (34) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (70) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (34) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.72M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 6.24M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 67.89M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 66.00M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 37.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 505,074 | Mar 14, 2022 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 14, 2022 |